Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation who received lenalidomide- or bortezomib-based regimens

自体干细胞移植 养生 沙利度胺
作者
Elena Zamagni,Sujith Dhanasiri,Arun Ghale,Adam J. Moore,Murielle Roussel
出处
期刊:Leukemia & Lymphoma [Taylor & Francis]
卷期号:62 (10): 2492-2501 被引量:5
标识
DOI:10.1080/10428194.2021.1924369
摘要

We aimed to compare real-world outcomes, resource use, and costs for patients with newly diagnosed multiple myeloma (NDMM) treated with continuous first-line (1 L) lenalidomide or fixed bortezomib in Europe. We performed a multicenter, retrospective, observational chart review of transplant-ineligible NDMM patients across 7 countries. Of 453 eligible patients, 220 received 1 L lenalidomide-based regimens; 105 (47.7%) received second-line (2 L) treatment, of which 50 (47.6%) received 2 L bortezomib. 233 patients received 1 L bortezomib-based regimens; 142 (60.9%) had 2 L treatment, of which 104 (73.2%) received 2 L lenalidomide. Patients receiving 1 L lenalidomide-based regimens had better progression-free survival than patients receiving 1 L bortezomib-based regimens (p = .002) and a longer time to 2 L or third-line treatment (both p < .05). Total treatment-associated monthly costs for patients receiving 1 L lenalidomide-based regimens (n = 171, €2,268.55) were significantly greater than for 1 L bortezomib-based regimens (n = 188, €1,724.77) (p < .001) over the follow-up period (median, 38.7 months).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
付博发布了新的文献求助10
2秒前
4秒前
无敌是多么寂寞完成签到,获得积分10
4秒前
科研达人发布了新的文献求助30
6秒前
6秒前
量子星尘发布了新的文献求助10
6秒前
7秒前
zz完成签到 ,获得积分10
7秒前
科研一路绿灯完成签到,获得积分10
7秒前
2024020847发布了新的文献求助10
9秒前
9秒前
10秒前
11秒前
紫色奶萨完成签到,获得积分10
12秒前
李安全完成签到,获得积分10
12秒前
12秒前
Strongly完成签到,获得积分10
14秒前
nannan发布了新的文献求助10
15秒前
16秒前
丘比特应助水流众生采纳,获得10
16秒前
16秒前
Melody发布了新的文献求助10
16秒前
汉堡包应助科研通管家采纳,获得10
17秒前
彭于晏应助科研通管家采纳,获得10
17秒前
老老实实好好活着完成签到,获得积分10
17秒前
大模型应助科研通管家采纳,获得10
17秒前
MchemG应助科研通管家采纳,获得10
17秒前
小二郎应助科研通管家采纳,获得10
17秒前
深情安青应助科研通管家采纳,获得10
17秒前
czh应助科研通管家采纳,获得10
17秒前
Ava应助科研通管家采纳,获得10
17秒前
17秒前
星辰大海应助科研通管家采纳,获得30
17秒前
17秒前
MchemG应助科研通管家采纳,获得10
17秒前
17秒前
NexusExplorer应助科研通管家采纳,获得10
17秒前
17秒前
SiDi发布了新的文献求助10
20秒前
22秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988975
求助须知:如何正确求助?哪些是违规求助? 3531316
关于积分的说明 11253424
捐赠科研通 3269917
什么是DOI,文献DOI怎么找? 1804830
邀请新用户注册赠送积分活动 882063
科研通“疑难数据库(出版商)”最低求助积分说明 809068